DEMOCRITE Project: Demonstrating the efficiency
of OPM-101 by targeting RIPK2 in Inflammatory Bowel Disease
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63;
Mnemonic: ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancer, announced today that it has received notice of the grant of
funding associated with the "i-Démo n°2" call for projects as part
of the France 2030 plan. The aim of this call for projects is to
develop industrial and service companies in growth markets that
create value and competitiveness for our economy and contribute to
the energy, ecological and digital transitions.
The government has allocated €5.6 M of funding to the DEMOCRITE
program for a total project cost of €12.5 M. The funding will be
provided as a grant (€1.7 M) and repayable advances (€3.9 M) for a
project period of 43 months.
OPM-101, developed from the Nanocyclix® platform, is currently
being administered to the last healthy volunteer in phase I trial
and is one of OPM's most advanced assets. The DEMOCRITE project, in
response to bpifrance's
I-Démo n°2 call for projects, aims to demonstrate the
efficiency of OPM-101 by targeting RIPK2 in Inflammatory Bowel
Diseases. More specifically, this project aims to fund the end of
phase 1 and phase 2a of our OPM-101 molecule for the treatment of
Immune-Induced Ulcerative Colitis (IIUC).
IIUC are:
- An immunological adverse effect intrinsically linked to the
action mechanism of immune checkpoint inhibitors (IPCI) represented
by anti-CTLA4 & anti-PD(L)1,
- One of the most frequent and severe effects of IPCI,
(particularly anti-CTLA4 (40% all grades) and anti-CTLA4 &
anti-PD1 combinations (>30% all grades))
Furthermore, there are strong similarities between Recto Colitis
Hemorrhagic (RCH) and IIUC. The main purpose of the DEMOCRITE
project for OPM is to demonstrate proof of concept of the
efficiency of OPM-101 in patients suffering from IIUC in order to
reach a commercial agreement with a pharmaceutical partner, while
continuing the development of OPM-101 for the treatment of UC.
OPM-101 is one of three molecules derived from our Nanocyclix®
kinase inhibitor technology administered to humans. Several other
molecules are currently being optimized for known and unexplored
kinases and will become tomorrow's targeted therapies in precision
medicine. The success of the DEMOCRITE project will enable OPM to
finance, develop and secure a precision medicine sector in France,
positioning OPM as a leader in the development of kinase
inhibitors.
Kinases play a key role in regulating most cellular functions,
such as proliferation, cell cycle progression, metabolism, survival
or apoptosis, repair of damaged DNA, motility, and response to the
microenvironment. This means that targeting kinases represents a
major opportunity in over 400 diseases.
Philippe GENNE, Co-founder, Chairman and CEO of Oncodesign
Precision Medicine, said: "This €5.6 million grant is
particularly significant for the company: the successful
development of OPM-101 is key to our growth. It comes at a time
when, like national and international biotechs, financing is more
difficult to obtain from investors, particularly on the stock
market. This project is perfectly in line with our strategy and
should enable OPM-101 to complete its phase 2a trial in IIUC
patients under the best possible conditions and without losing any
time. This support from the French government, as part of the
France 2030 program, is the fruit of an in-depth assessment of the
project and provides further confirmation of the interest in this
drug candidate, which represents a breakthrough innovation in the
treatment of patients suffering from severe colitis. We are
particularly proud and grateful for this national recognition,
which follows other recent successes with the COMETE and ANIMUS
projects. It proves that our country is giving itself the means to
build a strong healthcare industry for tomorrow".
Jan HOFLACK, Co-Founder and Chief Medical Officer of
Oncodesign Precision Medicine added: "OPM-101, a RIPK2
inhibitor molecule derived from our breakthrough Nanocyclix®
technology, continues its path towards proof of efficiency in
patients after its phase 1 trial, which demonstrated very
interesting properties in terms of pharmacokinetics, safety profile
and pharmacodynamics in healthy volunteers. Our product is
positioned in major markets and has the potential to bring real
benefits to patients suffering from multiple types of colitis. This
potential has been well understood by government experts in the
context of France 2030. OPM-101 has the potential to become a
"First-in-Class" and a "Best-in-Class" molecule, so it was
essential for us not to waste any time. Our RIPK2 inhibitors also
have the potential to become a real franchise, with promising
results obtained in immuno-oncology with our series of
molecules."
About France 2030
Presented on October 12, 2021, by the French President,
France 2030:
- Reflects a dual ambition: to transform key sectors of our
economy (energy, automotive, healthcare, aeronautics, and space)
through technological and industrial innovation, and to position
France not just as a player, but as a leader in the world of
tomorrow. From fundamental research to the emergence of an idea, to
the production of a new product or service, France 2030 supports
the entire life cycle of innovation, right through to
industrialization.
- Is unprecedented in its scale: €54 billion will be invested to
help our companies, universities and research organizations make
the transition in these strategic sectors a success. The aim is to
enable them to respond competitively to the ecological and
attractiveness challenges of the coming world, and to create the
future champions of our sectors of excellence, thereby
strengthening French sovereignty and independence in key sectors.
To this end, 50% of spending will be devoted to decarbonizing the
economy, and 50% will be earmarked for emerging players, bringing
innovation with no adverse impact on the environment (in line with
the Do No Significant Harm principle).
- Will be implemented collectively: the plan is designed and
deployed in consultation with local and European economic and
academic players, who have helped to determine its strategic
orientations and flagship actions. Project leaders are invited to
submit their applications via open, demanding, and selective
procedures, in order to benefit from government support.
- Managed by the Secrétariat Général pour l'Investissement on
behalf of the French Prime Minister and implemented by the Agence
de la Transition Ecologique (ADEME), the Agence Nationale de la
Recherche (ANR), Bpifrance and the Caisse des Dépôts et
Consignations (CDC).
For more information: france2030.gouv.fr
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), founded in 2022, is a
biopharmaceutical company specializing in precision medicine,
dedicated to the discovery of treatments for resistant and
metastatic cancers.
OPM currently has two kinase inhibitors in clinical trials:
OPM-101, for the treatment of chronic immuno-inflammatory digestive
diseases, which demonstrated a significant therapeutic margin and
lack of toxicity in phase I trials with healthy volunteers, with a
phase II trials in cancer patients with severe colitis induced by
treatment with immuno checkpoint inhibitors (CUII) scheduled to
start at the end of 2024. OPM-201, licensed to Servier for the
treatment of Parkinson's disease, completed its phase I trial in
healthy volunteers this year, with phase II scheduled to start in
2025.
Finally, a third kinase inhibitor, OPM-102, targeting oncology,
is in preclinical development.
These three molecules come from the Nanocyclix® technology
platform, which enables the design and selection of small
macrocyclic kinase inhibitors that are highly effective and
selective. We now have 12,000 molecules in our library and will be
using AI to accelerate the discovery of drug candidates while
reducing the cost of this phase.
OPM's two other technology platforms are:
- OncoSNIPER, for the selection of therapeutic targets using
artificial intelligence, in partnership with Servier for the search
of targets in pancreatic cancer,
- PROMETHE® for the design and selection of radiolabeled
biological molecules for systemic radiotherapy, for which we are
currently discussing partnerships with vectorization
companies.
OPM, co-founded by Philippe Genne, Jan Hoflack and Karine
Lignel, is based in Dijon, in the heart of the university and
hospital cluster, and has 22 employees.
Further information: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417449524/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)3 80
78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Grafico Azioni Oncodesign Precision Med... (EU:ALOPM)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Oncodesign Precision Med... (EU:ALOPM)
Storico
Da Ott 2023 a Ott 2024